Loading data for FDMT — first visit, this takes a few seconds.
4D Molecular Therapeutics... (FDMT)
NasdaqGS: FDMT
· Real-Time Price · USD
14.67
-0.24 (-1.61%)
At close: Aug 31, 2026, 11:45 AM
14.11
+0.00%
After-hours: 4:14 PM
The price, the headline numbers and the latest news, in one place.
4D Molecular Therapeutics Inc. (FDMT) Stock Price, Analysis & Data
-1.61% (1D)
| Bid | 10.75 |
| Market Cap | 779.5M |
| Revenue (ttm) | 92.01M |
| Net Income (ttm) | -179.18M |
| 2.69 | |
| -2.63 | |
| n/a | |
| -3.45 | |
| P/B (ttm) | 1.91 |
| P/S (ttm) | 8.47 |
| Earnings Date | Nov 10, 2026 |
| Ask | 14.44 |
| Volume | 1,101,306 |
| Avg. Volume (20D) | 950,603 |
| Open | 14.85 |
| Previous Close | 14.91 |
| Day's Range | 14.20 - 15.00 |
| 52-Week Range | 5.97 - 16.93 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injec...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 196
Stock Exchange NasdaqGS
Ticker Symbol FDMT
Financial Performance
In 2025, 4D Molecular Therapeutics's revenue was 85.21M, an increase of 230,194.59% compared to the previous year's 37K. Earnings were -140.11M, a decrease of -12.9%.
Financial StatementsEarnings Surprise
4D Molecular Therapeutics has released their quarterly earnings on Aug 13, 2026:
- Revenue of $3.05M misses estimates by $0, with 21664.29% YoY growth.
- EPS of -1.04 misses estimates by -0.02, with -6.12% YoY decline.
4D Molecular Therapeutics Inc. is scheduled to release its earnings on Nov 10, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2